Interim PET‐results for prognosis in adults with Hodgkin lymphoma: A systematic review and meta‐analysis of prognostic factor studies

Interim PET‐results for prognosis in adults with Hodgkin lymphoma: A systematic review and meta‐analysis of prognostic factor studies

Pokaži ostale verzije (1)

<p><strong>Background:</strong><br /> Hodgkin lymphoma (HL) is one of the most common haematological malignancies in young adults and, with cure rates of 90%, has become curable for the majority of individuals. Positron emission tomography (PET) is an imaging tool used to mon...

Bibliografski detalji
Glavni autori:	Aldin, A, Umlauff, L, Estcourt, LJ, Collins, G, Moons, KGM, Engert, A, Kobe, C, von Tresckow, B, Haque, M, Foroutan, F, Kreuzberger, N, Trivella, M, Skoetz, N
Format:	Journal article
Jezik:	English
Izdano:	Cochrane Collaboration 2020

Slični predmeti

Interim PET for prognosis in adults with Hodgkin lymphoma: A prognostic factor exemplar review
od: Skoetz, N, i dr.
Izdano: (2017)

Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
od: Aldin, A, i dr.
Izdano: (2019)

Prognostic models for newly‐diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta‐analysis
od: Kreuzberger, N, i dr.
Izdano: (2020)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
od: M. André, i dr.
Izdano: (2011-01-01)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
od: Akram Al-Ibraheem, i dr.
Izdano: (2022-10-01)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
od: Karan L. Chohan, i dr.
Izdano: (2022-12-01)

Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions.
od: Thomas W Georgi, i dr.
Izdano: (2023-01-01)

Simvastatin-dependent apoptosis in Hodgkin’s lymphoma cells and growth impairment of human Hodgkin’s tumors in vivo
od: Bastian von Tresckow, i dr.
Izdano: (2007-05-01)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
od: Dennis A. Eichenauer, i dr.
Izdano: (2022-10-01)

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD
od: Diego Villa, i dr.
Izdano: (2018-12-01)

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.
od: Thomas W Georgi, i dr.
Izdano: (2020-01-01)

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment
od: Elizabeth Katherine Anna Triumbari, i dr.
Izdano: (2022-09-01)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
od: Chiara Rusconi, i dr.
Izdano: (2022-10-01)

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
od: M. C. Pirosa, i dr.
Izdano: (2022-06-01)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
od: Arun Seshachalam, i dr.
Izdano: (2019-12-01)

S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL
od: P. Bröckelmann, i dr.
Izdano: (2022-06-01)

Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis (Protocol)
od: Skoetz, N, i dr.
Izdano: (2016)

P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET
Izdano: (2018-10-01)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
od: Chiara Rusconi, i dr.
Izdano: (2023-08-01)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
od: Jesko Momotow, i dr.
Izdano: (2019-10-01)

The role of FDG-PET in Hodgkin lymphoma
od: Edyta Subocz, i dr.
Izdano: (2017-06-01)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
od: Eleonora Calabretta, i dr.
Izdano: (2022-10-01)

P026 (0057) INTERIM- PET RESULTS FOR PROGNOSIS IN ADULTS WITH HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR EXEMPLAR REVIEW (PRELIMINARY RESULTS)
Izdano: (2018-10-01)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
od: Johanna Grund, i dr.
Izdano: (2022-10-01)

The utility of PET/CT with 18F-FDG in the study of Hodgkin's lymphoma and non-Hodgkin's lymphoma
od: Marta Milhões, i dr.
Izdano: (2015-11-01)

THE CHEMOKINE CCL17/TARC AS A BIOMARKER IN HODGKIN LYMPHOMA
od: Maike Sauer, i dr.
Izdano: (2013-08-01)

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
od: Tseng Diane, i dr.
Izdano: (2012-01-01)

Evidence of Inbreeding in Hodgkin Lymphoma.
od: Hauke Thomsen, i dr.
Izdano: (2016-01-01)

THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA
od: Dennis A Eichenauer, i dr.
Izdano: (2011-10-01)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
od: Paul Bröckelmann, i dr.
Izdano: (2023-08-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
od: Dennis A. Eichenauer, i dr.
Izdano: (2018-10-01)

The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria
od: Elske Quak, i dr.
Izdano: (2014-06-01)

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
od: Esther Natalie Oliva, i dr.
Izdano: (2024-03-01)

MRI versus CT and PET/CT in the Preoperative Assessment of Hodgkin and Non-Hodgkin Lymphomas
od: Francesca Maccioni, i dr.
Izdano: (2021-10-01)

Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma
od: Özgür Ömür, i dr.
Izdano: (2014-03-01)

Suicide in European Hodgkin Lymphoma Patients
od: Austin I. Kim, i dr.
Izdano: (2019-04-01)

Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review
od: Christine Herbst, i dr.
Izdano: (2010-03-01)

Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma
od: Berit Müller‐Meinhard, i dr.
Izdano: (2024-06-01)

Machine Learning to Predict Interim Response in Pediatric Classical Hodgkin Lymphoma Using Affordable Blood Tests
od: Jennifer A. Geel, i dr.
Izdano: (2024-10-01)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
od: Conrad-Amadeus Voltin, i dr.
Izdano: (2022-10-01)